Phesgo and Tecentriq Performance and Approvals

Hemophilia A: Hemlibra the global standard of care 37% US/EU-5 patient share reached CHFM 1,200 1,000 800 +33% 600 +146% 400 200 YoY CER growth +24% • +30% 0 Q1 20 Q121 Q122 Q1 23 US Europe International Japan CER-Constant Exchange Rates Q1 update . • ~20,000 patients treated globally Roche Hemlibra continues to penetrate across all approved patient segments • EU: Label extension to moderate patients (HAVEN 6) granted . Outlook 2023 • US/EU: Further patient share gains in non-inhibitors • SPK-8011 (dirloctocogene samoparvovec) pivotal Ph III to be initiated 24

View entire presentation